

ENG

Product Data Sheet:

**HUMAN GHRELIN ACYLATED
EASY SAMPLING ELISA**

Catalogue number:
RA194062500R

For research use only!

Example Version

| | | |
|-----|--|----|
| 1. | HUMAN GHRELIN ACYLATED EASY SAMPLING ELISA | 3 |
| 2. | PRECAUTION FOR USE | 4 |
| 3. | BACKGROUND | 4 |
| 4. | PRINCIPLE OF THE ASSAY | 6 |
| 5. | MATERIAL REQUIRED BUT NOT PROVIDED | 7 |
| 6. | SAMPLE COLLECTION AND PREPARATION | 7 |
| 7. | REAGENT PREPARATION | 9 |
| 8. | ASSAY PROCEDURE | 11 |
| 9. | DATA ANALYSIS | 14 |
| 10. | ACCEPTABLE RANGE | 14 |
| 11. | TYPICAL RESULTS | 15 |
| 12. | ASSAY VALIDATION AND CHARACTERISTICS | 16 |
| 13. | ASSAY TROUBLE SHOOTING | 23 |
| 14. | BIBLIOGRAPHY | 24 |
| 15. | EXPLANATION OF SYMBOLS | 25 |

1. HUMAN GHRELIN ACYLATED EASY SAMPLING ELISA

96 wells

Storage: -20°C

Expiry date: stated on the package

This kit contains:

| REAGENTS | COLOUR CODE | Quantity | Form |
|--|-----------------------|----------|-------------|
| Antibody Coated Microtiter Strips | Blister with zip | 1 | |
| Conjugate Solution (Human, rat tracer easy sampling) | Green | 1 vial | lyophilized |
| Human Acylated Ghrelin Standard | Blue with red septum | 2 | lyophilized |
| Quality Control | Green with red septum | 2 | lyophilized |
| Dilution Buffer (EIA buffer) | Blue | 1 | lyophilized |
| Wash Solution Conc. (400x) | Silver | 1 | liquid |
| Substrate Solution (Ellman's reagent) | Black with red septum | 2 | lyophilized |
| Tween 20 | Transparent | 1 | liquid |
| Cover Sheet | | 1 | |

Each kit contains sufficient reagents for 96 wells. This allows for the construction of one standard curve in duplicate and the assay of 36 samples in duplicate.

If you want to use the kit in two times, we provide one additional vial of Standard, one of Quality Control and one of Substrate Solution (Ellman's reagent).

2. PRECAUTION FOR USE

Users are recommended to read all instructions for use before starting work.

Each time a new pipette tip is used, aspirate a sample or reagent and expel it back into the same vessel. Repeat this operation two or three times before distribution in order to equilibrate the pipette tip.

- For research laboratory use only.
- Not for diagnostic use.
- Do not pipet liquids by mouth.
- Do not use kit components beyond the expiration date.
- Do not eat, drink or smoke in area in which kit reagents are handled.
- Avoid splashing.

Wearing gloves, laboratory coat and glasses is recommended when assaying kit materials and samples.

Temperature:

Unless otherwise specified, all the experiments are done at room temperature (RT), that is around +20°C. Working at +25°C or more affects the assay and decreases its efficiency.

3. BACKGROUND

Acetylcholinesterase AChE® Technology

Acetylcholinesterase (AChE®), the enzymatic label for EIA, has the fastest turnover rate of any enzymatic label. This specific AChE is extracted from the electric organ of the electric eel, *Electrophorus electricus*, and it's capable of massive catalytic turnover during the generation of the electrochemical discharges. The use of AChE as enzymatic label for EIA has been patented by the French academic research Institute CEA [1, 2, 3].

AChE® assays are revealed with Substrate Solution (Ellman's reagent) , which contains acetylthiocholine as a substrate. The final product of the enzymatic reaction (5-thio-2-nitrobenzoic acid), is bright yellow and can be read at 405-414 nm. AChE® offers several advantages compared to enzymes conventionally used in EIAs:

Kinetic superiority and high sensitivity

AChE® shows true first-order kinetics with a turnover of 64,000 sec⁻¹. That is nearly 3 times faster than Horse Radish Peroxidase (HRP) or alkaline phosphate. AChE® allows a greater sensitivity than other labeling enzymes.

Low background

non-enzymatic hydrolysis of acetylthiocholine in buffer is essentially absent. So, AChE® allows a very low background and an increased signal/noise ratio compared to other substrate of enzymes which is inherently unstable.

Wide dynamic range

AChE® is a stable enzyme and its activity remains constant for many hours as, unlike other enzymes, its substrate is not suicidal. This permits simultaneous assays of high diluted and very concentrated samples.

Versatility: AChE®

is a completely stable enzyme, unlike peroxidase which is suicidal. Thus, if a plate is accidentally dropped after dispatch of the AChE® substrate solution (Ellman's reagent) or if it needs to be revealed again, one only needs to wash the plate, add fresh Substrate Solution (Ellman's reagent) and proceed with a new development. Otherwise, the plate can be stored at +4°C with Wash Buffer in wals while waiting for technical advice from the Bioreagent Department.

Ghrelin

Ghrelin discovered in 1999, is fast becoming an endokrinology target of the millennium. Ghrelin, identified in rat stomach as an endogenous ligand for the GH secretagogue receptor, is mainly produced in stomach, but has been demonstrated in many other organs [4, 5]. In addition to GH-releasing properties and its orexant action, Ghrelin could act as an hormone having effects on gastric motility (similarity with the peptide hormone motilin), acidic secretion, cardiovascular action, antiproliferative effects, pancreatic and glucose metabolism function, sleep [6, 7, 8]...

Ghrelin gene raises to mRNA prepro-ghrelin of 117 amino acids. This precursor is processed into Ghrelin, 28 amino acids (human). Before being secreted, this peptide is octanoylated at Ser 3 by GOAT (Ghrelin Octanoyl Acyl Transferase). This step is Essentials for biological activity making GOAT a perfect target for drugs in feeding behaviour. Interestingly, the potential therapeutic importance of this hormone is not restricted to regulation of food intake [9] but also in cachexia (related to cancer treatment, anorexia nervosa or ischemia) [10] gastrin motility and may be involved in osteoporosis, somatopause, infertility and ovulation induction, neurological disorders (Alcoholism, Post Traumatic Stress disorders...) [11] and cardiovascular diseases.

4. PRINCIPLE OF THE ASSAY

This Enzyme Immunometric Assay (EIA) is based on a double antibody sandwich technique. The wells of the plate supplied are coated with a monoclonal antibody specific to the C-terminal part of Ghrelin.

This antibody will bind to any Ghrelin introduced into the wells (standard or sample). After a washing step, the acetylcholinesterase (AChE) - Fab' conjugate (Tracer) which recognises the N-terminal part of Acylated Ghrelin is also added to the wells.

The two antibodies then form a sandwich by binding on different parts of the Acylated Ghrelin.


The sandwich is immobilised on the plate so reagents in excess may be washed away.

The concentration of Acylated Ghrelin (human) is determined by measuring the enzymatic activity of immobilized Tracer using Substrate Solution (Ellman's Reagent). AChE Tracer acts on Substrate Solution (Ellman's Reagent) to form a yellow compound that strongly absorbs at 414 nm.

The intensity of the colour, which is determined by spectrophotometry, is proportional to the amount of Acylated Ghrelin (human) present in the well during the immunological incubation.

This ELISA so called Easy Sampling ELISA kit works with any sample collected on any kind of protease inhibitors, without extraction but a simple dilution.

The principle of the assay is summarised below:



5. MATERIAL REQUIRED BUT NOT PROVIDED

In addition to standard laboratory equipment, the following material is required:

FOR SAMPLE PREPARATION

- EDTA tubes for blood collection
- Protease inhibitor (AEBSF, PMSF, Aprotinin, Pefabloc®P800, PHMB)
- UltraPure water (cat. number S0001)

FOR THE ASSAY

- Precision micropipettes (20 to 1000 μ L)
- Spectrophotometer plate reader (405 or 414 nm filter)
- Microplate washer (or wash-bottles)
- Orbital Microplate shaker able to perform at 600 rpm
- Multichannel pipette and disposable tips 30-300 μ L
- Ultra pure water
- Polypropylene tubes

Water used to prepare all EIA reagents and buffers must be Ultra Pure, deionized & free from organic contaminants traces.

Otherwise, organic contamination can significantly affect the enzymatic activity of the tracer AcetylCholinesterase. Do not use distilled water, HPLC-grade water or sterile water.

- Ultra pure water may be purchased from BioVendor (cat. number S0001)

6. SAMPLE COLLECTION AND PREPARATION

General precautions

- All samples must be free of organic solvents prior to assay.
- Samples should be assayed immediately after collection or should be stored at -20°C .

Blood Collection

- Blood samples are collected in tubes containing EDTA and a protease inhibitor to prevent the degradation of Acylated Ghrelin.
- Choice of protease inhibitor
- We suggest adding AEBSF at 0.2 mg/mL blood during blood collection. We suggest preparing a 100 times concentrated solution of protease inhibitor and then adding 10 μ L of this solution per mL of blood. For example, for the AEBSF, prepare a mother solution at 20 mg/mL in UltraPure water and add 10 μ L of this solution per mL of blood. The mother solution may be stored one month at -20°C . We suggest using aliquots for AEBSF solution in order to avoid freezing/thawing cycles.

Other protease inhibitors could be used with the assay like Aprotinin (up to 0,6 TIU/mL blood), PMSF (around 0.1 mg/mL blood according to literature), PHMB, Pefabloc® or Pefabloc SC® (up to 0.2 mg/mL blood) as indicated in the section “Protease inhibitor compatibility table” at the end of this booklet. For the use of these different products, please refer to the vendor’s instructions.

- Collection tubes are mixed by inversion 5 folds.
Samples should be kept on ice between collection and centrifugation (15 minutes max).
- Blood samples are centrifuged at 3,500 rpm for 10 minutes at +4°C and then, supernatants are transferred in separate tubes. Samples should be quickly assayed or stored at -20°C or at -80°C for later use within 6 months.
- The best way is to assay the samples within 3 weeks after the collection date. Moreover, we suggest using aliquots for plasma samples (we suggest 250 µl per aliquot) in order to avoid freezing/thawing cycles.

Plasma samples prepared as above-mentioned can be assayed for Acylated Ghrelin with Acylated Ghrelin EIA kit or for Unacylated Ghrelin with Unacylated Ghrelin EIA kit.

Sample preparation

Plasma samples may be assayed directly without any extraction procedure after being diluted at **least to 1:2 in Dilution Buffer** in order to avoid matrix effect.

7. REAGENT PREPARATION

Each kit contains sufficient reagents for 96 wells. This allows for the construction of one standard curve in duplicate and the assay of 36 samples in duplicate.

If you want to use the kit in two times, we provide one additional vial of Standard, one of Quality Control and one of Substrate Solution (Ellman's reagent).

All reagents need to be brought to room temperature, around +20°C, prior to the assay.

Dilution Buffer

Reconstitute the vial Dilution buffer with 50 mL of UltraPure water. Allow it to stand 5 minutes until completely dissolved and then mix thoroughly by gentle inversion.

Stability at 4°C: 1 month

Acylated Ghrelin (human) Standard

Reconstitute the Standard vial with 1 mL of UltraPure water. Allow it to stand 5 minutes until completely dissolved and then mix thoroughly by gentle inversion.

The concentration of the first standard S1 is 250 pg/mL.

Prepare seven propylene tubes for the other standards and add 500 µL of Dilution Buffer into each tube. Then prepare the standards by serial dilutions as follows:

| Standard | Volume of Standard | Volume of Dilution Buffer | Standard concentration pg/mL |
|----------|--------------------|---------------------------|------------------------------|
| S1 | - | - | 250 |
| S2 | 500 µL of S1 | 500 µL | 125 |
| S3 | 500 µL of S2 | 500 µL | 62.5 |
| S4 | 500 µL of S3 | 500 µL | 31.3 |
| S5 | 500 µL of S4 | 500 µL | 15.6 |
| S6 | 500 µL of S5 | 500 µL | 7.8 |
| S7 | 500 µL of S6 | 500 µL | 3.9 |
| S8 | 500 µL of S7 | 500 µL | 2.0 |

Acylated Ghrelin (human) Quality Control

The Quality Control provided in this kit has been prepared by spiking Acylated Ghrelin (human) peptide in Dilution Buffer.

Reconstitute the Quality Control vial with 1 mL of UltraPure water. Allow it to stand 5 minutes until completely dissolved and then mix thoroughly by gentle inversion.

Stability at +4°C: 1 week

Acylated Ghrelin Conjugate Solution

Reconstitute the vial Conjugate Solution with 10 mL of Dilution Buffer. Allow it to stand 5 minutes until completely dissolved and then mix thoroughly by gentle inversion.

Stability at +4°C: 1 week

Wash Buffer

Dilute 2 mL of concentrated Wash Buffer with 800 mL of UltraPure water. Add 400 µL of Tween20. Use a magnetic stirring bar to mix the content.

Stability at +4°C: 1 week

Substrate Solution (Ellman's Reagent)

5 minutes before use (development of the plate), reconstitute one vial of Substrate Solution (Ellman's Reagent_49+1) with 49 mL of UltraPure water and 1 mL of concentrated Wash Buffer. The tube content should be thoroughly mixed.

Stability at 4°C and in the dark: 24 hours

Example Version

8. ASSAY PROCEDURE

It is recommended to perform the assays in duplicate and to follow the instructions hereafter.

Plate preparation

Prepare the Wash Buffer as indicated in the reagent preparation section. Open the plate packet and select the sufficient strips for your assay and place the unused strips back in the packet

Stability at +4°C: 1 month

Rinse each well 5 times with the Wash Buffer 300 µL/well.

Just before distributing reagents and samples, remove the buffer from the wells by inverting the plate and shaking out the last drops on a paper towel.

Plate set-up

A plate set-up is suggested on the following page.

The contents of each well may be recorded on the template sheet provided at the end of this technical booklet.

Pipetting the reagents

All samples and reagents must reach room temperature prior to performing the assay.

Use different tips to pipette the buffer, standard, sample, conjugate, antiserum and other reagents.

Before pipetting, equilibrate the pipette tips in each reagent. Do not touch the liquid already in the well when expelling with the pipette tip.

Dilution Buffer

Dispense 100 µL to Non Specific Binding NSB wells.

Acylated Ghrelin (human) Standards

Dispense 100 µL of each of the eight standards S1 to S8 in duplicate to appropriate wells.

Start with the lowest concentration standard S8 and equilibrate the tip in the next higher standard before pipetting.

Quality Control and samples

Dispense 100 µL in duplicate to appropriate wells. Highly concentrated samples may be diluted in Dilution Buffer.

Incubating the plate

Cover the plate with the cover sheet and incubate for 2 hours at room temperature on a orbital shaker (at 600rpm).

Washing the plate

Empty the plate by turning over. Rinse each well five times with 300 μ L Wash Buffer. The 5th time, slightly shake the plate for 5 minutes on an orbital shaker. Then rewash five times with 300 μ L Wash Buffer. At the end of the last washing step, empty the plate and blot the plate on a paper towel to discard any trace of liquid.

| | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 |
|---|-----|----|----|---|---|---|---|---|---|----|----|----|
| A | B | S2 | S6 | * | * | * | * | * | * | * | * | * |
| B | B | S2 | S6 | * | * | * | * | * | * | * | * | * |
| C | B | S3 | S7 | * | * | * | * | * | * | * | * | * |
| D | NSB | S3 | S7 | * | * | * | * | * | * | * | * | * |
| E | NSB | S4 | S8 | * | * | * | * | * | * | * | * | * |
| F | NSB | S4 | S8 | * | * | * | * | * | * | * | * | * |
| G | S1 | S5 | QC | * | * | * | * | * | * | * | * | * |
| H | S1 | S5 | QC | * | * | * | * | * | * | * | * | * |

B : Blank

S1-S8: Standards 1-8

* : Samples

NSB : Non Specific Binding

QC: Quality Controls

Pipetting the reagents

Acylated Ghrelin Conjugate Solution

Dispense 100 μ L to each well, except blank (Bk) wells.

Incubating the plate

Cover the plate with the cover sheet and incubate for 2 hours at room temperature on a orbital shaker (at 600rpm).

Developing and reading the plate

- Reconstitute Substrate Solution (Ellman's reagent) as mentioned in the Reagent preparation section.
- Empty the plate by turning over. Rinse each well five times with 300 μ L Wash Buffer. The 5th time, slightly shake the plate for 5 minutes on an orbital shaker. Then rewash five times with 300 μ L Wash Buffer. At the end of the last washing step, empty the plate and blot the plate on a paper towel to discard any trace of liquid.
- Add 200 μ L of Substrate Solution (Ellman's reagent) to each 96 well. Cover the plate with aluminium sheet and incubate in the dark at room temperature. Optimal development is obtained using an orbital shaker.
- Wipe the bottom of the plate with a paper towel, and make sure that no liquid has splashed outside the wells.
- Read the plate at a wavelength between 405 and 414nm (yellow colour).

After addition of Substrate Solution (Ellman's reagent), the absorbance has to be checked periodically (every 30 minutes) until the maximum absorbance has reached a minimum of 0.5 A.U. blank subtracted.

| Easy Sampling Enzyme Immunoassay Protocole (volumes are in μ L) | | | | |
|---|-------|-----|----------|--------------|
| | Blank | NSB | Standard | Sample or QC |
| Dilution Buffer | - | 100 | - | - |
| Standard | - | - | 100 | - |
| Sample or QC | - | - | - | 100 |
| Cover plate, incubate 2 hours at 600 rpm | | | | |
| Wash plate 5 times, shake 5 min, wash 5 times & discard liquid from the wells | | | | |
| Tracer | - | 100 | 100 | 100 |
| Cover plate, incubate 2 hours at 600 rpm | | | | |
| Wash plate 5 times, shake 5 min, wash 5 times & discard liquid from the wells | | | | |
| Ellman's reagent | 200 | | | |
| Incubate with an orbital shaker in the dark at RT | | | | |
| Read the plate between 405 and 414 nm | | | | |

9. DATA ANALYSIS

Make sure that your plate reader has subtracted the absorbance readings of the blank well (absorbance of Substrate Solution (Ellman's reagent) alone) from the absorbance readings of the rest of the plate. If not, do it now.

Calculate the average absorbance for each NSB, standard and sample.

For each standard, plot the absorbance on y axis versus the concentration on x axis. Draw a best-fit line through the points.

To determine the concentration of your samples, find the absorbance value of each sample on the y axis.

Read the corresponding value on the x axis which is the concentration of your unknown sample. Do not forget to integrate the dilution factor of your own samples (due notably to the minimal dilution for the assay 1:2).

Samples with a concentration greater than 250 pg/mL should be re-assayed after dilution in Dilution Buffer.

Most plate readers are supplied with curve-fitting software capable of graphing these data (logit/log or 4-parameter logistic fit 4PL). If you have this type of software, we recommend using it. Refer to it for further information.

Two vials of Quality Control are provided with this kit. Your standard curve is validated only if the calculated concentration of the Quality Control obtained with the assay is +/- 25% of the expected concentration (written on the Quality Control Sheet)

10. ACCEPTABLE RANGE

Non Specific Binding < 50 mA.U.

Limit of detection in the sample before dilution <2 pg/mL


QC sample: $\pm 25\%$ of the expected concentration (see on the Quality Control Sheet)

11. TYPICAL RESULTS

The following data are for demonstration purpose only. Your data may be different and still correct.

These data were obtained using all reagents as supplied in this kit under the following conditions: 60 minutes developing, fading at 414 nm. A 5-parameter logistic fitting ponderation 1/Y² was used to determine the concentrations.

| | Acylated Ghrelin (human) pg/mL | Absorbance (mAU) |
|-------------|--------------------------------|------------------|
| Standard S1 | 250 | 2875 |
| Standard S2 | 125 | 1518 |
| Standard S3 | 62.5 | 741 |
| Standard S4 | 31.3 | 324 |
| Standard S5 | 15.6 | 163 |
| Standard S6 | 7.8 | 81 |
| Standard S7 | 3.9 | 43 |
| Standard S8 | 2.0 | 28 |
| Blank | 0 | 10 |



Typical Human Acylated ghrelin Easy Sampling standard curve

12. ASSAY VALIDATION AND CHARACTERISTICS

Immunometric assay of Acylated Ghrelin (human) has been validated for its use in buffer and in plasma (without extraction but diluted at least 1:5). A sigmoidal logistic fitting ponderation 1/Y² was used to determine the concentrations .

For additional information regarding the validation of immunoassay for protein biomarkers in biological samples, please refer to bibliography [12, 13].

The **limit of detection**, calculated as the concentration of Acylated Ghrelin corresponding to the NSB average (n = 8) plus three standard deviations is 2 pg/mL. Due to the minimal plasma dilution (1:2), the limit of detection in the samples is less than 4 pg/mL.

Intra-assay & inter-assay variations and recovery:

| QC levels after 1:5 dilution (pg/mL) | Inter-assay | | | Intra-assay | | |
|--------------------------------------|---|--------|--------------|---|--------|--------------|
| | Mean of observed concentrations (pg/mL) | CV (%) | Recovery (%) | Mean of observed concentrations (pg/mL) | CV (%) | Recovery (%) |
| 200 (ULOQ) | 217.0 | 10.0 | 8.6 | 228.0 | 2.6 | 13.8 |
| 150 (HQC) | 163.0 | 7.0 | 8.5 | 167.0 | 2.8 | 11.6 |
| 50 (MQC) | 45.9 | 13.5 | -8.3 | 45.8 | 4.8 | -8.3 |
| 10 (LQC) | 9.6 | 20.1 | -4.2 | 9.0 | 15.1 | -10.1 |
| 5 (LLOQ) | 5.1 | 27.6 | -2.2 | 4.2 | 21.6 | -16.6 |

ULOQ: Upper Limit of Quantification
LQC: Low QC

HQC: High QC
LLOQ: Lower Limit of Quantification

MQC: Mid QC

The intra-assay and inter-assay variations were studied on a pool of human plasma containing AEBSF 0.4 mg/mL (free of Ghrelin) spiked samples for each level of QC. QC were prepared five times concentrated from a pool of human plasma and then diluted to 1:5 in Dilution Buffer before assay. For within-run precision and accuracy, the number of replicates (*n*) is equal to 6 for each levels of QC, the five QC samples were analysed along with the calibration curve for a unique experiment. For between-run precision and accuracy, the number of replicates (*n*) is equal to 6 for each levels of QC, the five QC samples were analysed along with the calibration curve for a total of 9 independent experiments.

Selectivity

| Matrix | Mean of measured concentration (pg/mL) | CV (%) | Recovery (%) |
|-----------------|--|--------|--------------|
| 1 | 6.49 | 3.18 | 29.7 |
| 2 | 6.05 | 3.53 | 20.9 |
| 3 | 6.14 | 4.95 | 22.7 |
| 4 | 6.35 | 2.18 | 26.9 |
| 5 (haemolysed) | 3.96 | 10.70 | -20.7 |
| 6 | 5.44 | 3.83 | 8.8 |
| 7 | 5.54 | 6.69 | 8.8 |
| 8 | 5.71 | 9.73 | 14.2 |
| 9 | 5.13 | 10.70 | 2.5 |
| 10 (haemolysed) | 3.66 | 4.26 | -26.7 |

Selectivity was tested by spiking 10 sources of samples matrix containing AEBSF at 0.4 mg/mL at the LLOQ (n=3).

These sources included 2 haemolysed samples (matrix 5 and 10).

QC samples (n=3) were prepared five times concentrated in each matrix (free of Ghrelin) and then diluted to 1:5 in Dilution buffer in order to obtain a final concentration of 5 pg/mL and analysed against a calibration curve.

Specificity

Specificity was tested by adding AEBSF at 0.4 mg/mL (recommended use concentration = reference) and 2 mg/mL (high concentration) or aprotinin at 1.2 TIU/mL with or without HCl 0.1 N final into sample matrix (a pool of human plasma samples) and measuring the accuracy of the Acylated Ghrelin (human) at both LLOQ and ULOQ (n=3).

| Matrix | QC level after 1:5 dilution (pg/mL) | Mean of measured concentration (pg/mL) | CV (%) | Recovery (%) |
|---------------------------------|-------------------------------------|--|--------|--------------|
| AEBSF 0.4 mg/mL | 5 | 5.25 | 9.23 | 4.91 |
| | 200 | 224 | 1.36 | 11.80 |
| AEBSF 0.4 mg/mL + HCl 0.1N | 5 | 5.17 | 7.62 | 3.32 |
| | 200 | 228 | 0.97 | 14.00 |
| AEBSF 2 mg/mL | 5 | 4.35 | 13.30 | -13.00 |
| | 200 | 200 | 1.09 | -0.13 |
| AEBSF 2mg/mL + HCl 0.1N | 5 | 4.91 | 11.20 | -1.72 |
| | 200 | 209 | 4.81 | 4.84 |
| Aprotinin 1.2 TIU/mL | 5 | 4.38 | 5.05 | -12.50 |
| | 200 | 211 | 1.32 | 5.66 |
| Aprotinin 1.2 TIU/mL + HCl 0.1N | 5 | 4.88 | 3.99 | -2.31 |
| | 200 | 215 | 3.54 | 7.31 |

Dilution tests

Dilution linearity was tested by spiking a pool of human plasma samples (free of Ghrelin) containing AEBSF at 0.4 mg/mL at 2000 pg/mL (n=3) and measuring precision and accuracy after serial dilution in Dilution buffer to bring the Acylated Ghrelin concentrations

into the validated range for analysis (between ULOQ and LLOQ).

| Dilution factor | Theoretical concentration (pg/mL) | Measured concentration (pg/mL) | Corrected concentration (pg/mL) | Recovery (%) | Mean Recovery (%) | CV% |
|-----------------|-----------------------------------|--------------------------------|---------------------------------|--------------|-------------------|------|
| 1:10 | 200 | 188.6 | 1886 | -5.69 | -1.33 | 5.27 |
| | | 206.6 | 2066 | 3.32 | | |
| | | 196.8 | 1968 | -1.62 | | |
| 1:20 | 100 | 90.9 | 1817 | -9.14 | -5.98 | |
| | | 99.7 | 1995 | -0.25 | | |
| | | 91.5 | 1829 | -8.55 | | |
| 1:40 | 50 | 46.3 | 1852 | -7.42 | -8.64 | |
| | | 46.7 | 1868 | -6.61 | | |
| | | 44.1 | 1763 | -11.90 | | |
| 1:80 | 25 | 22.2 | 1776 | -11.20 | -9.60 | |
| | | 22.2 | 1776 | -11.20 | | |
| | | 23.4 | 1872 | -6.41 | | |
| 1:160 | 12.5 | 11.1 | 1768 | -11.60 | -4.32 | |
| | | 12.7 | 2028 | 1.39 | | |
| | | 12.2 | 1945 | -2.74 | | |

Parallelism

Parallelism between the calibration standard curve and serial diluted samples was tested by diluting 3 samples containing AEBSF at 0.4 mg/mL in Dilution buffer (n=3) to bring the Acylated Ghrelin concentrations into the validated range for analysis (between ULOQ and LLOQ).

| Sample | Dilution series | Dilution factor | Measured concentration (pg/mL) | Corrected concentrations (pg/mL) | CV (%) |
|--------|-----------------|-----------------|--------------------------------|----------------------------------|--------|
| 1 | 1 | 1:5 | 13.30 | 66.3 | 29.3 |
| | | 1:10 | 6.60 | 66.0 | |
| | | 1:20 | 5.32 | 106.0 | |
| | 2 | 1:5 | 13.00 | 65.0 | 12.7 |
| | | 1:10 | 6.01 | 60.1 | |
| | | 1:20 | 2.52 | 50.4 | |
| | 3 | 1:5 | 10.80 | 54.0 | 10.0 |
| | | 1:10 | 4.70 | 47.0 | |
| | | 1:20 | 2.87 | 57.3 | |
| 2 | 1 | 1:2 | 13.80 | 27.6 | 18.8 |
| | | 1:5 | 4.06 | 20.3 | |
| | | 1:10 | 2.02 | 20.2 | |
| | 2 | 1:2 | 13.50 | 27.0 | 11.8 |
| | | 1:5 | 4.32 | 21.6 | |
| | | 1:10 | 2.29 | 22.9 | |
| | 3 | 1:2 | 15.20 | 30.4 | 16.7 |
| | | 1:5 | 4.52 | 22.6 | |
| | | 1:10 | 2.34 | 23.4 | |
| 3 | 1 | 1:2 | 14.80 | 29.7 | 15.5 |
| | | 1:5 | 4.72 | 23.6 | |
| | | 1:10 | 2.24 | 22.4 | |
| | 2 | 1:2 | 14.20 | 28.4 | 12.0 |
| | | 1:5 | 4.72 | 34.4 | |
| | | 1:10 | 2.29 | 22.9 | |
| | 3 | 1:2 | 13.90 | 27.7 | 9.2 |
| | | 1:5 | 4.82 | 24.1 | |
| | | 1:10 | 2.34 | 23.4 | |

Stability test (freezing/thawing, 24h at +5°C and 24h at +20/+25°C)

Stability of Acylated Ghrelin was evaluated by using Low and High QC samples. These QC samples (n=3) were prepared from a pool of human plasma (free of Ghrelin) containing AEBSF at 0.4 mg/mL or Aprotinin at 1.2 TIU/mL and then frozen at -20°C for freeze/thaw stability or stored 24h at +5°C or at 20/25°C for short-term stability.

| Conditions | QC level after 1:5 dilution (pg/mL) | Mean of measured concentration (pg/mL) | CV (pg/mL) | Recovery (%) |
|---|-------------------------------------|--|------------|--------------|
| Freeze/thaw 1 cycle AEBSF 0.4 mg/mL | 10 | 9.5 | 3.48 | -4.53 |
| | 150 | 165 | 1.93 | 10.30 |
| Freeze/thaw 3 cycles AEBSF 0.4 mg/mL | 10 | 11.0 | 10.90 | 10.10 |
| | 150 | 157 | 8.31 | 4.89 |
| Freeze/thaw 1 cycle Aprotinin 1.2 TIU/mL | 10 | 10.3 | 9.12 | 3.18 |
| | 150 | 156 | 8.81 | 4.18 |
| Freeze/thaw 3 cycles Aprotinin 1.2TIU/mL | 10 | 9.5 | 12.90 | -4.49 |
| | 150 | 150 | 3.79 | -0.15 |
| 24h at +5°C AEBSF 0.4 mg/mL | 10 | 8.0 | 3.52 | -20.20 |
| | 150 | 138 | 3.91 | 8.27 |
| 24h at 20/25°C AEBSF 0.4 mg/mL | 10 | 3.3 | 7.82 | -66.80 |
| | 150 | 65.4 | 3.90 | -56.40 |

Long term stability (3 and 6 months at -20°C & -80°C)

| Conditions | QC level after 1:10 dilution | Mean of measured concentration | CV (pg/mL) | Recovery (%) |
|-------------------|------------------------------|--------------------------------|------------|--------------|
| 3 months at -20°C | 10 | 8.33 | 4.17 | -16.70 |
| | 150 | 159 | 4.23 | 6.28 |
| 3 months at -80°C | 10 | 9.64 | 5.66 | -3.60 |
| | 150 | 171 | 2.19 | 14.20 |
| 6 months at -20°C | 10 | In progress | | |
| | 150 | In progress | | |
| 6 months at -80°C | 10 | In progress | | |
| | 150 | In progress | | |

Cross-reactivity

| Molecule / Species | Cross-reactivity |
|------------------------------|------------------|
| Acylated Ghrelin (rat) | 100 % |
| Acylated Ghrelin (dog) | 85 % |
| Unacylated Ghrelin (human) | <1 % |
| Unacylated Ghrelin (rat) | <1 % |
| Unacylated Ghrelin (dog) | <1 % |
| Ghrelin (1-14) (human) | <0.001 % |
| Ghrelin (1-11) (rat) | <0.001 % |
| Ghrelin (17-28) (human, rat) | <0.001 % |
| GHRF (human) | <0.001 % |
| Insulin (human) | <0.001 % |
| Motiline | <0.001 % |
| Leptin (human) | <0.001 % |
| Somatostatine | <0.001 % |
| CRF (human, rat) | <0.001 % |
| Glocagon (human, rat) | <0.001 % |

Protease Inhibitor compatibility table

| | AEBSF | PMSF | Pefabloc | P800 | Aprotinin | PHMB |
|--------------|-------|------|----------|------|-----------|------|
| RA194062500R | YES | YES | YES | YES | YES | YES |
| RA194062400R | NO | YES | NO | NO | YES | YES |

Plasma samples were collected on different protease inhibitors according to vendors instruction and measured with the appropriate kit. Recovery is different from one inhibitor to the other and it belongs to the end user to define according to its Leeds which inhibitor to be used. Acidification has also been tested with most inhibitors and may also change recovery, but will not affect the assay performances providing that 1:5 dilution with Dilution Buffer or neutralisation is performed.

13. ASSAY TROUBLE SHOOTING

Absorbance values too low:

- organic contamination of water
- one reagent has not been dispensed
- incorrect preparation/dilution
- assay performed before reagents reached room temperature)
- reading time not long enough

High signal and background in all wells:

- inefficient washing
- overdeveloping (incubation time should be reduced)
- high ambient temperature

High dispersion of duplicates:

- poor pipetting technique
- irregular plate washing










If a plate is accidentally dropped after dispatch of the AChE[®] substrate solution (Ellman's reagent) or if it needs to be revealed again:

- one only needs to wash the plate, add fresh Substrate Solution and proceed with a new development
- otherwise, the plate can be stored at +4°C with wash buffer in wells while waiting for technical advice from the Bioreagent Department.

14. BIBLIOGRAPHY

1. Grassi J, Pradelles P
Compounds labelled by the acetylcholinesterase of *Electrophorus Electricus*. Its preparation process and its use as a tracer or marquer in enzymo-immunological determinations. *United States patent, N° 1,047,330. September 10, 1991*
2. Grassi J, Pradelles P
The use of Acetylcholinesterase as a Universal marker in Enzyme-Immunoassays *Proceedings of the Third International Meeting on Cholinesterases, American Chemical Society (1991)*
3. Pradelles P, Grassi J, Maclouf J
Enzyme Immunoassays of Eicosanoids Using Acetylcholinesterase *Methods in Enzymology (1990), vol. 187, 24-34*
4. Kojima M, Kangawa KGhrelins: structure and function *Physiol. Rev (2005), 85:495-522,*
5. Bluet-Pajot MT, Tolle V, Zizzari P, Tomasetto C, Grouselle D, Epelbaum JGHrelins: A striking example of neuroendocrine peptide pleiotropy *Med Sci (Paris), August 1, 2005, 21 (8-9): 715-21*
6. de Faria Barros A et al
Is there association between acyl-ghrelin and inflammation in hemodialysis patients? *J Bras Nefrol. (2013) 35(2):120-126.*
7. Grouselle D et al Variations des peptides dérivés de la préproghréline au cours du repas dans l'anorexie mentale restrictive *Poster GIR-AFDAS-TCA2014*
8. Delhanty P et al
Des-acyl ghrelin analogs prevent high-fat-diet-induced dysregulation of glucose homeostasis *FASEB J. (2013) 27(4):1690-1700.*
9. Costantini, V et al
GSK1614343, a Novel Ghrelin Receptor Antagonist, Produces an Unexpected Increase of Food Intake and Body Weight in Rodents and Dogs *Neuroendocrinology (2011);94:158–168*
10. Porporato E, Filigheddu N et al
Acylated and unAcylated Ghrelin impair skeletal muscle atrophy in mice. *J. Clinical Invest (2013) 123(2): 611-622*
11. Sentissi O, Epelbaum J, Olié JP, Poirier MF
Leptin and Ghrelin Levels in Patients With Schizophrenia During Different Antipsychotics Treatment: A Review *Schizophrenia Bulletin (2008) 34(6), 1189–1199*
12. Valentin MA, Ma S, Zhao A, Legay F, Avrameas A
Validation of immunoassay for protein biomarkers: Bioanalytical study plan implementation to support pre-clinical and clinical studies. *J Pharm Biomed Anal. (2011) 55(5) : 869-877*
13. European Medicines Agency
Guideline on bioanalytical method validation, 21 July 2011

15. EXPLANATION OF SYMBOLS

| | |
|---|---|
|  | Catalogue number |
|  | Batch code |
|  | Caution |
|  | Use by date |
|  | Temperature limit |
|  | Manufacturer |
|  www.biovendor.com | Read electronic instructions for use - eIFU |
|  | The content is sufficient for 96 tests |
|  | Biological risks |



BioVendor – Laboratorní medicína a.s.
Karásek 1767/1, 621 00 Brno, Czech Republic
+420 549 124 185
info@biovendor.com
sales@biovendor.com
www.biovendor.com

Example Version

